Filtration in Biologics Market: Trends, Growth Drivers and Opportunities (2024–2034)

This report by Towards Healthcare, a sister firm of Precedence Research, provides an in-depth analysis of the filtration in biologics market. It highlights key trends, growth drivers, and emerging opportunities shaping the industry from 2024 to 2034.

Ottawa, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The filtration in biologics market is set for significant growth from 2024 to 2034, fueled by rising global demand for monoclonal antibodies, vaccines, and cell and gene therapies. Innovations in bioprocessing technologies, coupled with expanding biologics manufacturing, are driving the adoption of advanced filtration systems.

Increasing focus on product purity, regulatory compliance, and cost-effectiveness further strengthens market growth. Moreover, ongoing investments in R&D and biologics production infrastructure are creating new opportunities, particularly in emerging economies.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5798

Key Takeaways

North America dominated the global filtration in the biologics market with a revenue share of 46.9% in 2024.
Asia Pacific is expected to be the fastest-growing region in the upcoming years (2025–2030).
By filtration type, the microfiltration segment led the market by capturing 31.4% revenue share in 2024.
By filtration type, the virus filtration segment is expected to grow fastest during the forecast period.
By product type, the membrane filters segment dominated the market with a 57.1% share and is expected to grow at the fastest CAGR during the forecast period.
By biologic type, the monoclonal antibodies (mAbs) segment held the 48.6% revenue share of the market in 2024.
By biologic type, the cell & gene therapies segment is expected to register rapid growth over the projected period. 
By process stage, the downstream processing segment was dominant with 62.3% revenue share of the global filtration in the biologics market in 2024.
By process stage, the final fill/finish segment is expected to show the fastest growth in the predicted timeframe.
By end user, the biopharmaceutical companies segment led with 66.2% revenue share of the market in 2024.
By end user, the CMOs/CDMOs segment is expected to grow rapidly during the forecast period.

Market Overview & Potential

The filtration in the biologics market refers to the use of filtration technologies in the manufacturing and purification of biologic drugs such as monoclonal antibodies (mAbs), vaccines, recombinant proteins, and cell & gene therapies. Primarily, the market is propelled by the rising demand for purification and sterilisation of biologics, biosimilars, and vaccines. With a focus on this factor, recently, several advancements in depth filtration, virus filtration, and sterile filtration, with improved efficiency, throughput, and sustainability, are boosting the market expansion. However, another trend is accelerating, such as automation, predictive maintenance, and the use of advanced materials, including nanofiber technology.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What Is The Growth Potential Responsible For The Growth Of The Filtration In the Biologics Market?

The main drivers for filtration in the biologics market are the increasing production of complex biologics, stringent regulatory requirements for safety and purity, and growing demand for advanced filtration technologies like single-use systems and membrane filtration. The need to remove impurities, viruses, and endotoxins is paramount, as is the expansion of cell and gene therapies, which necessitate rigorous, specialised filtration.

What Are The Growing Trends Associated With The Filtration In the Biologics Market?

Single-use systems:

The adoption of single-use filtration technologies is a major trend, driven by their cost-effectiveness, reduced risk of cross-contamination, and increased scalability.

Tangential Flow Filtration (TFF):

TFF systems are seeing high demand due to their effectiveness in concentrating and purifying biologics, with the market projected to grow significantly.

Virus filtration:

As regulatory requirements for viral clearance become more stringent, the demand for efficient and reliable virus filtration systems is rising, with this sub-market showing robust growth.

Technological innovation:

Manufacturers are focusing on developing new membrane materials and improving the efficiency of existing filtration systems to meet the growing needs of biologics manufacturing.

Digitalisation:

There is a growing opportunity to leverage digitalisation for real-time monitoring and predictive maintenance of filtration systems to improve process control and efficiency.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

What Is The Growing Challenge In The Filtration In the Biologics Market?

Key challenges in biologics filtration include the high cost of advanced filtration systems and ongoing operational expenses, which can lead to reduced product yield and speed. Other challenges involve stringent and evolving regulatory requirements, the complexity of handling large and complex biological molecules, and the emergence of alternative technologies that compete with traditional filtration methods.

Regional Analysis

How Did North America Dominate The Filtration In the Biologics Market In 2024?

North America dominated the global filtration in the biologics market with a revenue share of 46.9% in 2024. North America dominates the biologics filtration market, driven by advanced biomanufacturing infrastructure and the presence of major players in the U.S. and Canada. High investments in biologics R&D, especially monoclonal antibodies and gene therapies, are accelerating demand for precision filtration solutions. Regulatory emphasis on product safety and adoption of single-use filtration systems further strengthen the region’s leadership in biologics production.

What Made The Asia Pacific Significantly Grow In The Filtration In the Biologics Market In 2024?

Asia Pacific is expected to be the fastest-growing region in the upcoming years (2025–2030). Asia Pacific is rapidly emerging as a major biologics manufacturing hub, supported by growing investments in biotechnology across China, India, and South Korea. The region’s increasing focus on biosimilar production and expansion of CDMO capabilities is boosting filtration demand. Favourable government initiatives and rising clinical research activities are further enhancing market adoption of advanced microfiltration and virus filtration technologies.

Download the single region market report @ https://www.towardshealthcare.com/checkout/5798

Segmental Insights

By filtration type, 

The microfiltration segment led the market by capturing 31.4% revenue share in 2024. Microfiltration plays a critical role in biologics manufacturing by removing cell debris and particulate contaminants from process streams. It is mainly used in upstream and clarification steps to ensure media purity and protect downstream processes. The growing adoption of automated, single-use microfiltration systems is improving operational efficiency, sterility, and product yield across biopharmaceutical production facilities.

The virus filtration segment is expected to grow fastest during the forecast period. Virus filtration is a key downstream process ensuring viral safety in biologics such as monoclonal antibodies and recombinant proteins. It uses nanometer-scale membranes to remove viral particles without affecting product integrity. Increasing regulatory scrutiny for viral clearance and the rise of cell and gene therapy manufacturing are driving the adoption of advanced virus filtration membranes and systems.

By product type, 

The membrane filters segment dominated the market with a 57.1% share and is expected to grow at the fastest CAGR during the forecast period. Membrane filters represent the largest product category, offering high selectivity and reproducibility for bioprocess filtration. They are widely used in sterile filtration, virus removal, and clarification steps. Continuous improvements in membrane materials, such as hydrophilic polymers and asymmetric pore structures, are enhancing throughput and retention efficiency, making them vital for large-scale biologics manufacturing operations.

By biologic type,

The monoclonal antibodies (mAbs) segment held the 48.6% revenue share of the market in 2024. Filtration is crucial in monoclonal antibody (mAb) production to ensure purity, safety, and efficacy. It is used throughout the production process from cell culture clarification to virus removal. With rising global demand for therapeutic antibodies, manufacturers are increasingly integrating advanced tangential flow and virus filtration systems to maintain consistency and comply with stringent regulatory requirements.

The cell & gene therapies segment is expected to register rapid growth over the projected period. In cell and gene therapy manufacturing, filtration ensures sterile processing and viral vector purification. Advanced nanofiltration and microfiltration techniques are critical for ensuring product safety without compromising therapeutic potency. The increasing number of approved gene therapies and expansion of viral vector production capacity are fueling demand for highly specialised filtration technologies tailored to small-batch biologics.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

By process stage,

The downstream processing segment was dominant with 62.3% revenue share of the global filtration in the biologics market in 2024. Downstream filtration plays a vital role in separating and purifying biologic products. It encompasses virus removal, ultrafiltration, and sterile filtration to meet quality and safety standards. Manufacturers are increasingly adopting integrated, single-use filtration systems to streamline purification workflows, reduce contamination risk, and enhance productivity across biologics and biosimilar production lines.

The final fill/finish segment is expected to show the fastest growth in the predicted timeframe. The final fill and finish stage requires stringent sterile filtration to prevent microbial contamination before packaging. This step ensures product integrity and patient safety. High-performance microfilters and integrity testing systems are widely used to comply with Good Manufacturing Practice (GMP) standards. Automation and closed-system designs are enhancing precision and sterility during final drug formulation.

By end user,

The biopharmaceutical companies segment led by 66.2% revenue share of the market in 2024. Biopharmaceutical companies represent the dominant end users, utilising filtration technologies across both development and commercial manufacturing. These firms rely on advanced filtration solutions to produce monoclonal antibodies, vaccines, and gene therapies at scale. The growing focus on process optimisation, contamination control, and regulatory compliance continues to drive investment in next-generation filtration systems and consumables.

The CMOs/CDMOs segment is expected to grow rapidly during the forecast period. Contract manufacturing and development organisations are rapidly expanding filtration usage to handle diverse biologics portfolios. Flexible, modular, and single-use filtration solutions enable faster turnaround and scalable production. The outsourcing trend in biologics manufacturing continues to boost demand for high-throughput and regulatory-compliant filtration technologies.

Browse More Insights of Towards Healthcare:

The global biologics safety testing market is valued at USD 4.03 billion in 2024, rising to USD 4.58 billion in 2025, and is projected to reach approximately USD 14.45 billion by 2034, expanding at a CAGR of 13.64% during 2025–2034.

The subcutaneous biologics market is estimated at USD 1.89 billion in 2024, expected to grow to USD 2.1 billion in 2025, and further reach around USD 5.37 billion by 2034, reflecting a CAGR of 11.09% over the forecast period.

The biologics contract research organization (CRO) market was valued at USD 31.15 billion in 2024, projected to increase to USD 35.22 billion in 2025, and is anticipated to reach approximately USD 106.28 billion by 2034.

The biologics CDMO market stood at USD 22 billion in 2024, rose to USD 25.41 billion in 2025, and is forecasted to attain around USD 92.79 billion by 2034, registering a strong CAGR of 15.48% from 2025 to 2034.

The spine biologics market is expected to advance at a CAGR of 5.20%, growing from USD 4.65 billion in 2025 to USD 7.34 billion by 2034 during the forecast period.

The cancer biologics market is projected to expand from USD 119.41 billion in 2025 to approximately USD 232.02 billion by 2034, witnessing a CAGR of 7.66% throughout 2025–2034.

The retinal biologics market is anticipated to grow from USD 27 billion in 2025 to USD 53.61 billion by 2034, achieving a CAGR of 7.92% over the forecast years.

The global biologics market is poised for substantial expansion, increasing from USD 485.19 billion in 2025 to about USD 938.04 billion by 2034, driven by a CAGR of 7.6% during the forecast period.

Recent Developments

In June 2025, Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens, and assay kits, launched a novel line of Human Hybrid IgM Control Monoclonal Antibodies for research applications.
In February 2025, Zydus Lifesciences unveiled a vaccine used for the new strain of the influenza virus.
In October 2024, Asahi Kasei Medical launched the Planova™ FG1, a next-generation virus removal filter with higher flux for the manufacture of biotherapeutics.

Filtration in Biologics Market Key Players List

Merck KGaA (MilliporeSigma)
Sartorius AG
Danaher Corporation (Cytiva & Pall Life Sciences)
Thermo Fisher Scientific
3M Health Care (formerly Purification Solutions)
Repligen Corporation
Parker Hannifin (Bioscience Division)
GE Healthcare Life Sciences (now Cytiva)
Meissner Filtration Products
Asahi Kasei Medical (Planova filters)
EMD Millipore
Amazon Filters Ltd.
Cole-Parmer
Saint-Gobain Life Sciences
Sterlitech Corporation

Download the Competitive Landscape market report @ https://www.towardshealthcare.com/checkout/5798

Segments Covered in The Report

By Filtration Type 

Microfiltration
- Cell harvesting
- Clarification
Ultrafiltration
- Protein concentration
- Buffer exchange (UF/DF)
Nanofiltration
- Endotoxin removal
- Protein separation 
Virus Filtration
- Viral clearance 
- Mycoplasma control 
Sterile Filtration 
- Final fill
- Aseptic processing

By Product Type

Membrane Filters
- Microfiltration
- Ultrafiltration
- Nanofiltration
- Reverse Osmosis
Pre-filters & Depth Media
Single-Use Systems (e.g., Cartridges, Capsules)
Filtration Accessories (e.g., Housings, Filter Holders)
Others

By Biologic Type

Monoclonal Antibodies (mAbs)
Vaccines
Recombinant Proteins
Cell & Gene Therapies
Blood-derived Products
Shape, Picture

By Process Stage

Upstream Processing
Media filtration
Cell culture harvesting
Downstream Processing
Clarification
Purification
Concentration
Final Fill/Finish
Sterile filtration
Particulate removal
Shape, Picture

By End User

Biopharmaceutical Companies
CMOs/CDMOs
Academic & Research Institutes
Clinical Research Organisations

By Region

North America
- U.S.
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Latin America
- Brazil
- Mexico
- Argentina
Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/5798

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.